Advanced Immunolabeling Reagents and Tools from Vector Laboratories Now from Bio-Techne

MINNEAPOLIS, Jan. 15, 2018 /PRNewswire/ -- Bio-Techne now offers reagents and kits from Vector Laboratories, a leader in advanced labeling and detection solutions. Their innovative proprietary immunolabeling kits offer reliable, sensitive, and low background detection. In October 2017, Bio-Techne started distributing Vector Laboratories' flagship products to complement its vast selection of Novus Biologicals® primary antibodies, including over 13,000 monoclonal- and over 36,000 polyclonal-antibodies, validated for immunohistochemistry or immunocytochemistry. By combining Novus Biologicals® primary antibodies with secondary detection reagents from Vector Laboratories, researchers have access to powerful tools to achieve clear and crisp immunostaining.

Several reagents from Vector Laboratories are currently available at novusbio.com for distribution within the continental United States including:

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact: Dave Eansor, Senior Vice President, Biotech Division, 612-379-2956

View original content with multimedia:http://www.prnewswire.com/news-releases/advanced-immunolabeling-reagents-and-tools-from-vector-laboratories-now-from-bio-techne-300582227.html

SOURCE Bio-Techne Corporation